The primary efficacy endpoints will be pain relief, and diminished nausea, photophobia, and phonophobia.

GlaxoSmithKline gets FDA nod for combination migraine treatment

Migraine headaches are common in children and occur with increasing frequency through adolescence. The reported prevalence increases from 3% (age three to seven years) to 4%-11% (age seven to 11 years) to 8%-23% (age 11 to 15 and up). The mean age at onset is 7.2 years for boys and 10.9 years for girls.

Elan's Frova is approved for migraine

Side-effects cause 66% of migraine headache sufferers to frequently delay or skip medication doses, according to a survey by the National Headache Foundation.